BioTech

Abiomed heart pump gets second FDA emergency use nod for COVID-19 patients

Credit: REUTERS/JASON REED

Medical device maker Abiomed Inc said on Tuesday the U.S. Food and Drug Administration granted its left-sided heart pumps emergency use authorization to help patients suffering from COVID-19-related heart and lung failures.

Aug 4 (Reuters) - Medical device maker Abiomed Inc ABMD.O said on Tuesday the U.S. Food and Drug Administration granted its left-sided heart pumps emergency use authorization to help patients suffering from COVID-19-related heart and lung failures.

COVID-19, the respiratory disease caused by the new coronavirus, causes widespread inflammation which could impair or damage the left ventricle of the heart and lead to heart failure or excess fluids in the lungs.

Impella, part of a family of invasive heart pump devices manufactured by Abiomed, provides circulatory support to patients who develop left side ventricular failure and is authorized to be used by healthcare providers in the hospital setting.

It was approved for use in the United States in 2015.

This is the second EUA that the FDA has granted for Impella during the COVID-19 pandemic. In May, the FDA issued an EUA to expand the use of Impella RP to include patients suffering from COVID-19-related right ventricular complications.

(Reporting By Mrinalika Roy in Bengaluru; Editing by Amy Caren Daniel)

((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABMD

Other Topics

US Markets

Latest Technology Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More